Anzeige
Mehr »
Login
Donnerstag, 09.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
NurExone Biologic: Erfahren Sie mehr über den Biotech-Gral!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
162 Leser
Artikel bewerten:
(0)

Weifa ASA: Invitation to presentation of Weifa's Q2 2016 results, Thursday 25 August

Oslo, 18 August 2016

Weifa ASA (OSE: WEIFA), Norway's leading consumer health company, will release its second quarter 2016 results on Thursday 25 August 2016.

The results will be presented by Weifa's CEO Kathrine Gamborg Andreassen and CFO Simen Nyberg-Hansen at 08:30 CET at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. Following the presentation, there will be a Q&A session. The presentation will be held in English.

The presentation will also be webcast live and can be accessed directly from http://webtv.hegnar.no/presentation.php?webcastId=36207825 (http://webtv.hegnar.no/presentation.php?webcastId=36207825)or http://www.weifa.no/webcast (http://www.weifa.no/webcast).
Questions may be submitted live during the presentation.

The quarterly report and the presentation materials will be available on www.weifa.com/investor (http://www.weifa.com/investor) and www.newsweb.no (http://www.newsweb.no/), as well as on news wires.

Weifa welcomes all interested parties.

For further information, please contact:

Simen Nyberg-Hansen
CFO
+47 9820 6355
simen.nyberg-hansen@weifa.no

Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Boers (ticker WEIFA). For further information, please visit: www.weifa.no (http://www.weifa.no/)

 
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Weifa ASA via Globenewswire

HUG#2035879
© 2016 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.